keyword
MENU ▼
Read by QxMD icon Read
search

CT-P13

keyword
https://www.readbyqxmd.com/read/27885553/biosimilars-for-the-treatment-of-chronic-inflammatory-diseases-a-systematic-review-of-published-evidence
#1
REVIEW
Ira Jacobs, Danielle Petersel, Leah Isakov, Sadiq Lula, K Lea Sewell
BACKGROUND: Clinicians are required to assimilate, critically evaluate, and extrapolate information to support appropriate use of biosimilars across indications. OBJECTIVES: The objective of this study was to systematically collate all published data in order to assess the weight (quantity and quality) of available evidence for each molecule and inform and support healthcare decision-making in chronic inflammatory diseases. METHODS: MEDLINE(®), EMBASE(®), and ISI Web of Science(®) were searched to September 2015...
December 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/27807766/monoclonal-antibody-and-fusion-protein-biosimilars-across-therapeutic-areas-a-systematic-review-of-published-evidence
#2
REVIEW
Ira Jacobs, Danielle Petersel, Lesley G Shane, Chee-Keng Ng, Carol Kirchhoff, Gregory Finch, Sadiq Lula
BACKGROUND: Despite regulatory efforts to formalize guidance policies on biosimilars, there remains a need to educate healthcare stakeholders on the acknowledged definition of biosimilarity and the data that underpin it. OBJECTIVES: The objectives of the study were to systematically collate published data for monoclonal antibodies and fusion protein biosimilars indicated for cancer, chronic inflammatory diseases, and other indications, and to explore differences in the type and weight (quantity and quality) of available evidence...
November 2, 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/27758715/efficacy-safety-and-immunogenicity-of-biosimilars-in-inflammatory-bowel-diseases-a-systematic-review
#3
Laura Martelli, Laurent Peyrin-Biroulet
BACKGROUND: Anti-tumor necrosis factor (anti-TNF) monoclonal antibodies have revolutionized the treatment of inflammatory bowel diseases (IBD). However, because of their complexity, their production is expensive contributing to their high price. As the patent protection of these therapies has expired in several countries, biosimilars have been developed to reduce the healthcare costs. The aim of this article is to review the literature on the safety, efficacy and immunogenicity of biosimilars in IBD...
October 14, 2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27739122/efficacy-of-ustekinumab-after-failure-of-infliximab-ct-p13-in-a-hla-cw6-positive-patient-affected-by-pityriasis-rubra-pilaris-monitoring-with-reflectance-confocal-microscopy-rcm-and-optical-coherence-tomography-oct
#4
LETTER
A Paganelli, S Ciardo, G Odorici, G Pellacani, A Conti
No abstract text is available yet for this article.
October 14, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27729659/biosimilars-in-ibd-from-theory-to-practice
#5
REVIEW
Silvio Danese, Stefanos Bonovas, Laurent Peyrin-Biroulet
Biologic agents have revolutionized the care management of many life-threatening and debilitating diseases. As patents for older biologic therapies have begun to expire, the market has opened to copy versions of the originators - commonly referred to as biosimilars, follow-on biologic agents or subsequent-entry biologic agents - which are expected to gain a portion of the market, reduce health-care spending and increase treatment access worldwide. Importantly for patients with IBD, CT-P13 was the first biosimilar to infliximab that obtained regulatory approval by the European Medicines Agency in September 2013 and by the FDA in April 2016...
October 12, 2016: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27711946/-biosimilars-in-inflammatory-bowel-disease
#6
B Siegmund, R Atreya, B Bokemeyer, W Kruis, J Mudter, C Sander, S Schreiber, W Reindl, S Zeissig, T Kucharzik
After the expiry date of the patent protection for Infliximab in 2013, the biosimilar CT‑P13 was approved for indications in Crohn's disease and ulcerative colitis in adults as well as in children. The approval has been based on two randomized clinical studies indicating equivalence for the biosimilar with regard to pharmacokinetics, efficacy, as well as side-effects. The clinical experience since, in addition to multiple non-randomized studies, indicate a comparable efficacy and immunogenicity of the Infliximab biosimilar CT-P13 in inflammatory bowel disease...
October 6, 2016: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/27660339/switching-from-remicade%C3%A2-to-remsima%C3%A2-is-well-tolerated-and-feasible-a-prospective-open-label-study
#7
Lydia C T Buer, Bjørn A Moum, Milada Cvancarova, David J Warren, Asle W Medhus, Marte Lie Høivik
BACKGROUND AND AIMS: A biosimilar version of infliximab [CT-P13/Remsima®] recently entered the European market. The clinical data on its use in inflammatory bowel disease [IBD] are sparse, especially on switching from the originator Remicade®. In this study, we aimed to prospectively investigate the feasibility, safety and immunogenicity of switching from Remicade to Remsima in a real-life IBD population. METHODS: All adult patients who were treated with Remicade in the Department of Gastroenterology at Oslo University Hospital were switched to Remsima...
September 22, 2016: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/27650650/infliximab-biosimilar-ct-p13-infliximab-dyyb-a-review-in-autoimmune-inflammatory-diseases
#8
Hannah A Blair, Emma D Deeks
Infliximab biosimilar (CT-P13/infliximab-dyyb; Remsima(®), Inflectra(®)) is approved in several countries for use in all indications for which reference infliximab (Remicade(®)) is approved, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Clinical data contributing to the EU approval of infliximab biosimilar were obtained from two pivotal double-blind clinical trials in patients with AS (PLANETAS) or RA (PLANETRA)...
October 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/27638739/biosimilar-monoclonal-antibodies-for-inflammatory-bowel-disease-current-comfort-and-future-prospects
#9
Krisztina B Gecse, Péter L Lakatos
Biosimilars are biologic medicines that enter the market after a patent for an original reference product expires. The European Medicines Agency (EMA) developed a stringent legislation process for biosimilar monoclonal antibodies, whereby similarity to the reference medicinal product in terms of quality characteristics, biological activity, clinical safety and efficacy must be demonstrated. Biosimilar infliximab CT-P13 was the first biosimilar monoclonal antibody to receive EMA marketing authorization, and further biosimilar molecules are being developed...
October 2016: Drugs
https://www.readbyqxmd.com/read/27586879/safety-and-efficacy-of-ct-p13-in-japanese-patients-with-rheumatoid-arthritis-in-an-extension-phase-or-after-switching-from-infliximab
#10
Yoshiya Tanaka, Hisashi Yamanaka, Tsutomu Takeuchi, Makoto Inoue, Kazuyoshi Saito, Yukihiko Saeki, Sang Joon Lee, Yoshihiro Nambu
OBJECTIVES: This study aimed to evaluate the safety of CT-P13 in patients with rheumatoid arthritis (RA) during long-term treatment or after switching from innovator infliximab (IFX). METHODS: Patients who completed 54 weeks of treatment in a phase I/II study (PI/II) received CT-P13 at an initial dose of 3 mg/kg at Week 62, with dose increases permitted up to 10 mg/kg. The primary endpoint was adverse event (AE) incidence. RESULTS: Thirty-four of 38 patients in the maintenance group and 29 of 33 in the switch group reported at least one AE...
September 1, 2016: Modern Rheumatology
https://www.readbyqxmd.com/read/27582886/experience-with-biosimilar-infliximab-ct-p13-in-paediatric-patients-with-inflammatory-bowel-diseases
#11
REVIEW
Joanna Sieczkowska, Dorota Jarzębicka, Monika Meglicka, Grzegorz Oracz, Jaroslaw Kierkus
Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression of the disease, probably also decreasing morbidity and hospitalization rates, and improving patients' comfort. When the patent on infliximab started to expire, the first biosimilar of a monoclonal antibody was introduced onto the pharmacological market...
September 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27564646/a-critical-review-of-biosimilars-in-ibd-the-confluence-of-biologic-drug-development-regulatory-requirements-clinical-outcomes-and-big-business
#12
Christina Y Ha, Asher Kornbluth
On February 9, 2016, the Food and Drug Administration Arthritis Advisory Committee recommended by a vote of 21 to 3, that the biosimilar to infliximab, CT-P13, be approved for rheumatoid arthritis and ankylosing spondylitis and, by extrapolation, for all the indications for which infliximab is currently approved, including adult and pediatric ulcerative colitis and Crohn's disease. On April 5, 2016, the Food and Drug Administration concurred with this recommendation and approved CT-P13 (Inflectra; Pfizer Inc...
October 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27473452/the-infliximab-biosimilar-in-the-treatment-of-moderate-to-severe-plaque-psoriasis
#13
Paolo Dapavo, Igor Vujic, Maria Teresa Fierro, Pietro Quaglino, Martina Sanlorenzo
BACKGROUND: The infliximab originator's patent recently expired, leading to the production of biosimilar versions of the drug. The biosimilars' efficacy was not tested on patients with psoriasis but most regulatory authorities approved their use in psoriasis because of an extrapolation of data from studies conducted in other diseases. OBJECTIVE: We sought to describe the use of the infliximab biosimilar (Remsima; CT-P13) in patients with psoriasis. METHODS: Objective (Psoriasis Area and Severity Index) and subjective (visual analog pain scale) measurements of disease activity were collected in 2 cohorts of patients with moderate to severe plaque psoriasis: cohort 1 patients switched from the infliximab originator to the infliximab biosimilar; and cohort 2 patients were infliximab-naïve and started on the infliximab biosimilar...
October 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27435444/ct-p13-inflectra%C3%A2-remsima%C3%A2-monitoring-in-patients-with-inflammatory-bowel-disease
#14
Kornelius Schulze, Nadine Koppka, Frederik Lutter, Gunnar Brandhorst, Stefan Schreiber, Ulf Helwig
The approval of infliximab biosimilars Remsima™ and Inflectra™ (CT-P13) for patients with inflammatory bowel disease (IBD) is a promising step to reduce treatment costs. Since monitoring of Remicade™ serum trough levels and anti-Remicade™ immunogenicity hold an important significance in treatment modalities, no data about monitoring of drug serum trough levels or anti-drug antibody levels in IBD patients treated with Remsima™ or Inflectra™ are present to date. Therefore, in this study we applied a Remicade™-validated ELISA to determine drug serum levels of Remsima™ or Inflectra™...
September 2016: Biologicals: Journal of the International Association of Biological Standardization
https://www.readbyqxmd.com/read/27162107/pharmacology-and-metabolism-of-infliximab-biosimilars-a-new-treatment-option-in-inflammatory-bowel-diseases
#15
REVIEW
Marcin Włodarczyk, Jakub Fichna, Aleksandra Sobolewska-Włodarczyk
Biological therapy with monoclonal antibodies to tumor necrosis factor alpha (TNF-α) was shown in large clinical trials to be effective in inducing and maintaining clinical remission in patients with moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). Infliximab, the first anti-TNF-α biologic drug, has significantly improved inflammatory bowel disease (IBD) treatment outcomes by preventing structural damage progression, thereby reducing complications and the need for surgery and hospitalization...
August 2016: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/27134662/clinical-experience-with-infliximab-biosimilar-remsima-ct-p13-in-inflammatory-bowel-disease-patients
#16
REVIEW
Jørgen Jahnsen
Many reference biological therapies have now reached or are near to patent expiry, and therefore a number of biosimilars have been or will be developed. The term biosimilar can be defined as a biotherapeutic product that is similar in efficacy, safety and quality to the licensed reference product. Biosimilars may lead to a reduced price and significant cost savings for the health community and hopefully more patients globally will have easier access to biological therapy when indicated. CT-P13, which is a TNF-alfa inhibitor, is the first monoclonal antibody biosimilar being used in clinical practice...
May 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27130908/efficacy-and-safety-of-ct-p13-biosimilar-infliximab-in-patients-with-rheumatoid-arthritis-comparison-between-switching-from-reference-infliximab-to-ct-p13-and-continuing-ct-p13-in-the-planetra-extension-study
#17
Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, Pedro Miranda, Edgar Ramiterre, Allan Lanzon, Asta Baranauskaite, Piotr Wiland, Carlos Abud-Mendoza, Boycho Oparanov, Svitlana Smiyan, HoUng Kim, Sang Joon Lee, SuYeon Kim, Won Park
OBJECTIVES: To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions. METHODS: This open-label extension study recruited patients with RA who had completed the 54-week, randomised, parallel-group study comparing CT-P13 with RP (PLANETRA; NCT01217086). CT-P13 (3 mg/kg) was administered intravenously every 8 weeks from weeks 62 to 102...
April 29, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27117857/switching-to-biosimilar-infliximab-ct-p13-evidence-of-clinical-safety-effectiveness-and-impact-on-public-health
#18
REVIEW
Jürgen Braun, Alex Kudrin
CT-P13, the biosimilar of infliximab, has been recently approved in the EU, Australia, Canada, Japan and many other countries. Thus, it was the first biosimilar approved in the field of rheumatology, dermatology and gastroenterology. Since there has been debate about the issue of switching from RMP to the biosimilar and some national societies have expressed concerns, this review was written with the following objectives: The review concludes that whilst prudent switching practices should be employed, growing safety experience accumulated thus far with CT-P13 and other biosimilars is favorable and does not raise any specific concerns...
July 2016: Biologicals: Journal of the International Association of Biological Standardization
https://www.readbyqxmd.com/read/27117698/efficacy-and-safety-of-switching-from-reference-infliximab-to-ct-p13-compared-with-maintenance-of-ct-p13-in-ankylosing-spondylitis-102-week-data-from-the-planetas-extension-study
#19
Won Park, Dae Hyun Yoo, Pedro Miranda, Marek Brzosko, Piotr Wiland, Sergio Gutierrez-Ureña, Helena Mikazane, Yeon-Ah Lee, Svitlana Smiyan, Mie-Jin Lim, Vladimir Kadinov, Carlos Abud-Mendoza, HoUng Kim, Sang Joon Lee, YunJu Bae, SuYeon Kim, Jürgen Braun
OBJECTIVES: To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS). METHODS: This open-label extension study recruited patients with AS who completed a 54-week, randomised controlled study comparing CT-P13 with RP (PLANETAS). CT-P13 (5 mg/kg) was administered intravenously every 8 weeks from week 62 to week 102. Efficacy end points included the proportion of patients achieving Assessment of SpondyloArthritis international Society (ASAS)20...
April 26, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27111634/corrigendum
#20
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Expert Review of Gastroenterology & Hepatology
keyword
keyword
97571
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"